Alector ALEC

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.07 (-4.43%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Alector (ALEC)
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $1.44

  • Market Cap

    $142.68 Million

  • Price-Earnings Ratio

    -1.17

  • Total Outstanding Shares

    99.09 Million Shares

  • Total Employees

    238

  • Dividend

    No dividend

  • IPO Date

    February 7, 2019

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    131 oyster point blvd., suite 600, South san francisco, CA, 94080

  • Homepage

    https://www.alector.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

January 1, 2024 to December 31, 2024
MetricValue
Net Cash Flow From Operating Activities$-229.91 Million
Net Cash Flow, Continuing$-41.23 Million
Net Cash Flow From Investing Activities$107.13 Million
Net Cash Flow From Financing Activities$81.54 Million
Net Cash Flow From Operating Activities, Continuing$-229.91 Million
Net Cash Flow From Investing Activities, Continuing$107.13 Million

Income Statement

January 1, 2024 to December 31, 2024
MetricValue
Net Income/Loss Available To Common Stockholders, Basic$-119.05 Million
Revenues$100.60 Million
Research and Development$185.94 Million
Income/Loss From Continuing Operations Before Tax$-118.90 Million
Net Income/Loss$-119.05 Million
Other Operating Expenses$54.21 Million

Comprehensive Income

January 1, 2024 to December 31, 2024
MetricValue
Comprehensive Income/Loss$-118.97 Million
Other Comprehensive Income/Loss$77,000
Other Comprehensive Income/Loss Attributable To Parent$77,000
Comprehensive Income/Loss Attributable To Parent$-118.97 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

Balance Sheet

January 1, 2024 to December 31, 2024
MetricValue
Other Non-current Liabilities$206.44 Million
Equity$126.80 Million
Noncurrent Assets$43.49 Million
Current Liabilities$125.06 Million
Accounts Payable$2.21 Million
Noncurrent Liabilities$216.44 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ALEC from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.